icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Paris France
11-15 April 2018
Back grey_arrow_rt.gif
Has increased rollout of direct acting antiviral therapy decreased the burden of late presentation and advanced liver disease in patients starting Hepatitis C Virus therapy in Germany?
  Reported by Jules Levin
EASL 2018 April 11-25 Paris France
Jurgen K Rockstroh1, Christoph Boesecke1, Patrick Ingiliz2, Florian Berger3, Karl-Georg Simon4, Thomas Lutz5, Knud Schewe6,Julian Schulze zur Wiesch7, Dietrich Hueppe8, Stefan Christensen9, Stefan Mauss3 for the GECCO study group 1University Hospital Bonn, Bonn, Germany; 2Center for Infectiology Berlin (CIB), Berlin, Germany; 3Center for HIV and Hepatogastroenterology, Dusseldorf, Germany; 4Practice for Gastroenterology Leverkusen, Leverkusen, Germany; 5Infektiologikum, Frankfurt, Germany; 6Infektionsmedizinisches Centrum Hamburg, Hamburg, Germany;7 University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 8Practice for Gastroenterology Herne, Herne, Germany; 9CIM Infectious Diseases, Munster, Germany